News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

MediciNova, Inc. Receives Notice of an Australian Patent Allowance for a Method of Treating Neuropathic Pain


4/24/2012 10:11:47 AM

SAN DIEGO, April 23, 2012 (GLOBE NEWSWIRE) -- MediciNova Inc, a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the Jasdaq Market of the Osaka Securities Exchange (Code Number: 4875), today announced that it has received a Notice of Allowance from the Australian Government Patent Office for a pending patent application that covers the use of ibudilast (MN-166) for the treatment of multiple forms of chronic neuropathic pain. MN-166 is the company's lead drug development candidate for certain neurological conditions, including progressive forms of multiple sclerosis, neuropathic pain and drug addiction.

Read at GlobeNewswire

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES